Development of the ulcerative colitis project PN-943 continues.
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
If lirentelimab reduces eosinophils in diseases characterised by eosinophil accumulation, why doesn’t it work?
Ipsen hopes to draw a line under its earlier deal-making snafu with a bet on Genfit, and investors have just over a year’s wait for the proof.
After years of U-turns Arena's pivot to bowel disease pays off, with a $6.7bn takeout bid.